In a report released today, Graham Doyle from UBS maintained a Buy rating on Alcon (ALC – Research Report), with a price target of CHF78.00. The company’s shares closed yesterday at $81.18.
Doyle covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Alcon, and GE Healthcare Technologies Inc. According to TipRanks, Doyle has an average return of -6.2% and a 48.61% success rate on recommended stocks.
Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $85.47, which is a 5.28% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $86.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $86.20 and a one-year low of $63.58. Currently, Alcon has an average volume of 801K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alcon (ALC) Company Description:
Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.
Read More on ALC:
